Key Accounts Director (North Central)

Summit Therapeutics Inc.; Atlanta (GA); On-site; USD 140,000 - 190,000; Full time

Job summary

Summit Therapeutics Inc. in Atlanta, GA field-based role seeks a Key Account Director to establish and maintain strategic relationships with IDNs, academic centers, regional health systems, and community provider networks to accelerate product adoption in oncology.

The role collaborates with Medical Affairs, Legal, Marketing and Commercial teams to integrate Summit’s therapies into provider pathways, negotiate favorable contracts, and build long-term partnerships across multiple products.

Responsibilities

• Translate national brand and access strategies into actionable engagement plans across IDNs, Academic Centers, regional health systems, and select parent accounts of community provider networks.
• Lead account strategy and execution focused on accelerating clinical pathway and treatment protocol inclusion post-launch, in close partnership with Medical Affairs,Legal, Marketing, and Commercial functions.
• Establish andmaintainbusiness-to-business and C-suite relationships with aligned key accounts to support educational programs, market access initiatives, and strategic partnerships.
• Build and sustain strong multi-level relationships with healthcare decision-makers, including P&T and formulary committee members, executive pharmacy leadership, C-suite executives, and service line leaders, across key oncology accounts (IDNs, Academic Centers, regional health systems, and community network parent organizations).
• Lead cross-functional collaboration with Commercial field teams to proactivelyidentifyand resolve access or reimbursement barriers.
• Track and analyze business opportunities and market dynamics to provide strategic and tactical insights that inform access and commercial strategy.
• Negotiate favorable contracts and agreements aligned with enterpriseobjectivesand market access strategy.
• Champion the voice of the customer internally by sharing insights with brand teams, field leadership, and market access stakeholders.
• Manage relationships andidentifyopportunities with select access stakeholders (e.g., NCODA, COA,OncareAlliance).
• Provide ongoing strategic feedback and insights to Commercial leadershipregardingmarket dynamics, pathway decisions, and account priorities.
• Develop mid- to long-term strategic engagement plans that support multiple product andindicationlaunches, with a focus on building partnerships beyond transactional contracting.
• Facilitate executive exchanges between Summit Therapeutics leadership and senior executives across IDNs, Academic Centers, regional health systems, and parent accounts of community provider networks.
• Maintain consistent, compliant engagement with healthcare decision-makers, including P&T and formulary committee members, executive pharmacy leadership,

Job description

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Location: Atlanta, GA Field Based

Overview of Role:

TheKey Account Director(KAD)is responsible forestablishingand maintaining strategic relationships that enableoptimalmarket access for Summit Therapeutics’ innovative oncology medicines. This includes engagement across IDNs, Academic Centers, regional health systems, and select parent accounts of community provider networks. These are regionally aligned positions, with each Key Account Director responsible for a defined geography and correspondingaccounts.

The Key Account Director will develop and execute strategic account plans designed to support rapid product adoption through clinical pathway and treatment protocol inclusion, while representing Summit Therapeutics with key executive decision-makers across key oncology accounts (IDNs, Academic Centers, regional health systems, and community network parent organizations). This Market Access role also coordinates cross-functional collaboration across Commercial, Medical Affairs, Legal, and Marketing, to ensure alignment and successful integration of Summit’s therapies within provider-drivenpathways.

Role and Responsibilities:

• Translate national brand and access strategies into actionable engagement plans across IDNs, Academic Centers, regional health systems, and select parent accounts of community provider networks.
• Lead account strategy and execution focused on accelerating clinical pathway and treatment protocol inclusion post-launch, in close partnership with Medical Affairs,Legal, Marketing, and Commercial functions.
• Establish andmaintainbusiness-to-business and C-suite relationships with aligned key accounts to support educational programs, market access initiatives, and strategic partnerships.
• Build and sustain strong multi-level relationships with healthcare decision-makers, including P&T and formulary committee members, executive pharmacy leadership, C-suite executives, and service line leaders, across key oncology accounts (IDNs, Academic Centers, regional health systems, and community network parent organizations). .
• Lead cross-functional collaboration with Commercial field teams to proactivelyidentifyand resolve access or reimbursement barriers.
• Track and analyze business opportunities and market dynamics to provide strategic and tactical insights that inform access and commercial strategy.
• Negotiate favorable contracts and agreements aligned with enterpriseobjectivesand market access strategy.
• Champion the voice of the customer internally by sharing insights with brand teams, field leadership, and market access stakeholders.
• Manage relationships andidentifyopportunities with select access stakeholders (e.g., NCODA, COA,OncareAlliance).
• Provide ongoing strategic feedback and insights to Commercial leadershipregardingmarket dynamics, pathway decisions, and account priorities.
• Develop mid- to long-term strategic engagement plans that support multiple product andindicationlaunches, with a focus on building partnerships beyond transactional contracting.
• Facilitate executive exchanges between Summit Therapeutics leadership and senior executives across IDNs, Academic Centers, regional health systems, and parent accounts of community provider networks.
• Maintain consistent, compliant engagement with healthcare decision-makers, including P&T and formulary committee members, executive pharmacy leadership,